Oncolytics Biotech Inc. (ONCY)

NASDAQ: ONCY · Real-Time Price · USD

1.020

+0.160 (18.56%)

At close: Aug 13, 2025, 4:00 PM

1.020

0.00 (0.00%)

Pre-market: Aug 14, 2025, 9:16 AM EDT

Oncolytics Biotech Employees

Oncolytics Biotech had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.

Employees

28

Change

-1

Growth

-3.45%

Revenue / Employee

n/a

Profits / Employee

-$796,374

Market Cap

102.05M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	28	-1	-3.45%
Dec 31, 2022	29	3	11.54%
Dec 31, 2021	26	1	4.00%
Dec 31, 2020	25	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

ONCY News

2 days ago - Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders - PRNewsWire
6 days ago - Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep - PRNewsWire
6 days ago - Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange - PRNewsWire
9 days ago - Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results - PRNewsWire
16 days ago - Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - PRNewsWire
21 days ago - Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential - PRNewsWire
22 days ago - Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules - PRNewsWire
4 weeks ago - Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types - PRNewsWire